• Christopher Moriates, Alanna Boulton, Blair Walker, Rachel Holliman, Nicholaus Christian, John Weems, Emily Humphry, Sara Young, Richard Bottner, and Jennifer Potter.
• Department of Internal Medicine, Dell Medical School at The University of Texas at Austin, Austin, Texas, USA.
• J Hosp Med. 2023 Dec 1; 18 (12): 110911121109-1112.

AbstractThis Brief Report includes follow-up data about the sustainability and expansion of the Buprenorphine Team (B-Team), a hospital-based opioid treatment (HBOT) program. Between September 2018 and January 2023, the B-Team started 398 patients with opioid-use disorder (OUD) on buprenorphine therapy and coordinated outpatient care for 353 patients before discharge. Two-hundred and forty-nine of these patients were scheduled for follow-up at our partner addiction treatment clinic. Retention rates at our partner clinic remain relatively high: 73 patients (36% of eligible patients) continued to attend appointments between 6 and 12 months, and 40 of 180 patients (22%) who have been discharged from the hospital for at least 1 year continued to attend appointments. This model has been adopted at three additional Texas hospitals, resulting in rapid growth: 1037 patients were started on buprenorphine across these four sites during 2021-2022. Our longitudinal results support HBOT as an effective model for treating patients with OUD.© 2023 Society of Hospital Medicine.

25 keywords...

hide…